Clinical Trial

177LuPSMA in Renal Cell Carcinoma

Study acronym: LASER
Active, Not Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This study aims to evaluate the efficacy and safety of 177Lu-PSMA-617 as a systemic therapy in patients with PSMA-positive advanced clear cell renal cell carcinoma (ccRCC). The name of the study drug involved in this research study is: -177Lu-PSMA-617 (a type of radioligand therapy)
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-05-07.
Status change: Not Yet Recruiting → Active, Not Recruiting 2026-02-23
Trial Details
NCT Number NCT06964958
Lead Sponsor Dana-Farber Cancer Institute
Collaborators: Novartis
Conditions Renal Cell Carcinoma, Advanced Clear Cell Renal Cell Carcinoma, Kidney Cancer
Enrollment 24 participants
Start Date 2025-07-31
Primary Completion 2026-12-01 (estimated)
Study Completion 2028-12-01 (estimated)
Updated on ClinicalTrials.gov 2026-02-24